Chargement en cours...
The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia
The FLT3 inhibitor gilteritinib has clinical activity in patients with FLT3‐mutated (FLT3 (mut+)) relapsed/refractory (R/R) acute myeloid leukemia (AML). The impact of FLT3 mutation clearance and the achievement of composite complete remission (CRc) and complete remission/complete remission with par...
Enregistré dans:
| Publié dans: | Cancer Med |
|---|---|
| Auteurs principaux: | , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2020
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7897940/ https://ncbi.nlm.nih.gov/pubmed/33340276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3652 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|